Avandia Sales StabilizingSales of GlaxoSmithKline's (GSK) Avandia have been significantly negatively impacted due to safety concerns, but it appears sales are close to stabilizing. We believe that sales are now at or very near their bottom. While sales of Avandia have been cut in half from their peak level reached in 2006, it remains a very important product, and stabilizing sales represents very good news.Generics a Predominant IssueOther than the Avandia issue, Glaxo still has to deal with generic erosion of a number of drugs including Coreg IR, Flonase, Wellbutrin XR, Paxil, Lamictal, Requip, Valtrex and Imitrex. On the positive front, we continue to be impressed by the vaccine franchise and look forward to the contribution from Rotarix, Promacta and Synflorix. And although we were disappointed by the recent delay with Cervarix, ...